Amicus Therapeutics, Inc. (FOLD) Receives “Buy” Rating from Cowen and Company
Cowen and Company restated their buy rating on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in a research report sent to investors on Tuesday, July 11th. They currently have a $16.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $10.00.
“This morning, FOLD announced that after more recent FDA talks and written.”,” the firm’s analyst commented.
Other research analysts have also issued research reports about the stock. BidaskClub upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a research note on Friday, June 16th. J P Morgan Chase & Co set a $13.00 target price on shares of Amicus Therapeutics and gave the stock a buy rating in a report on Monday, June 5th. Chardan Capital reaffirmed a buy rating and issued a $12.50 price objective on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Bank of America Corporation decreased their price objective on shares of Amicus Therapeutics from $10.00 to $9.00 and set a buy rating for the company in a research note on Thursday, May 25th. Finally, Zacks Investment Research raised shares of Amicus Therapeutics from a sell rating to a hold rating in a research note on Tuesday, March 21st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $13.42.
Shares of Amicus Therapeutics (FOLD) traded up 5.06% during trading on Tuesday, hitting $13.90. The stock had a trading volume of 3,148,323 shares. The firm’s market cap is $1.99 billion. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $14.05. The firm’s 50-day moving average is $11.40 and its 200 day moving average is $8.12.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. During the same quarter last year, the business posted ($0.40) earnings per share. On average, analysts expect that Amicus Therapeutics will post ($1.44) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/cowen-and-company-reiterates-buy-rating-for-amicus-therapeutics-inc-fold-updated-updated-updated.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were acquired at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $8.00, for a total transaction of $239,312.00. Following the sale, the insider now owns 474,438 shares in the company, valued at $3,795,504. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in FOLD. Vanguard Group Inc. increased its position in shares of Amicus Therapeutics by 4.2% in the first quarter. Vanguard Group Inc. now owns 8,687,760 shares of the biopharmaceutical company’s stock worth $61,944,000 after buying an additional 353,949 shares in the last quarter. Palo Alto Investors LLC increased its stake in Amicus Therapeutics by 23.0% in the first quarter. Palo Alto Investors LLC now owns 7,882,988 shares of the biopharmaceutical company’s stock worth $56,206,000 after buying an additional 1,472,958 shares during the period. Janus Capital Management LLC increased its stake in Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock worth $50,883,000 after buying an additional 244,906 shares during the period. Morgan Stanley increased its stake in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Amicus Therapeutics by 0.9% in the first quarter. State Street Corp now owns 5,766,929 shares of the biopharmaceutical company’s stock valued at $41,118,000 after buying an additional 50,982 shares during the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.